The Only Randomized Caloric Restriction Trial in Humans Slowed the Pace of Aging by Three Percent. It Also Took Two Percent Off the Hip.
Cutting calories extends lifespan in rodents. That result has been reproduced for close to a century, and it is the reason caloric restriction sits underneath most of modern geroscience, including the drug work on rapamycin, acarbose and the GLP-1 class. The obvious question is whether it does anything comparable in a person, and there is exactly one randomized controlled trial designed to find out. CALERIE Phase 2 ran for two years at three American research centres, randomized 220 healthy adults who were not overweight to a 25 percent cut in energy intake or to eating normally, and measured almost everything. It has now generated more than a decade of published analyses. This is a review of what those analyses found, including the parts that do not fit on a headline: the restriction people actually managed, the single aging clock that moved out of six that were tested, the two percent that came off the femoral neck, and what happened to testosterone in the men.
Key Takeaways: What the CALERIE Caloric Restriction Evidence Actually Shows
CALERIE Phase 2 was a National Institute on Aging funded randomized controlled trial that assigned 220 healthy non-obese adults, men aged 21 to 50 and premenopausal women aged 21 to 47 with a body mass index between 22.0 and 28.0, to two years of 25 percent caloric restriction or ad libitum eating in a roughly two-to-one ratio across three sites. Participants did not achieve the prescribed restriction: measured intake reduction averaged 15.2 percent at month 12 and 11.9 percent across the full 24 months, so every published CALERIE result describes moderate restriction rather than the 25 percent the protocol asked for. Weight loss peaked at 8.3 kilograms at month 12 and settled at 7.6 kilograms, about 10.4 percent of body weight, at month 24, of which roughly 5.4 kilograms was fat mass and 2.0 kilograms was fat-free mass. Cardiometabolic risk factors improved substantially, with LDL cholesterol falling from 97 to 90 milligrams per decilitre, triglycerides from 102 to 88, systolic blood pressure down 2.2 and diastolic down 3.4 millimetres of mercury, fasting insulin and HOMA-IR down 20 to 30 percent, and C-reactive protein down roughly 40 to 50 percent relative to controls. Of six DNA methylation aging measures tested, only DunedinPACE moved, slowing the estimated pace of aging by roughly 2 to 3 percent, while PhenoAge, GrimAge, the Horvath clock and the Hannum clock showed no significant change. Bone mineral density fell in the restricted group at all three measured sites over 24 months, with the lumbar spine at minus 0.013 grams per square centimetre against plus 0.007 in controls, the total hip at minus 0.017 against plus 0.001, and the femoral neck at minus 0.015 against minus 0.005, amounting to roughly 2 percent lower density at the spine and femoral neck alongside rising bone resorption markers. In the men, sex hormone binding globulin rose significantly at months 12 and 24 and free testosterone fell at month 12 before returning toward baseline by month 24, while measured sexual function did not deteriorate and the sexual drive and relationship subscale improved at month 24. No caloric restriction trial in humans has measured lifespan, mortality or incident disease, and CALERIE enrolled nobody over 50, so the evidence base says nothing directly about restriction in older men.
What was the CALERIE trial and why does it carry so much weight?
CALERIE Phase 2 is the only long-term randomized controlled trial of caloric restriction ever run in healthy humans, which is why a field with thousands of observational papers keeps returning to one study. The acronym stands for Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy. The National Institute on Aging funded it, and it ran at Washington University in St. Louis, the Pennington Biomedical Research Center in Baton Rouge and Tufts University in Boston. Enrolment was deliberately narrow. Participants had to be healthy, aged 21 to 50 for men and 21 to 47 for premenopausal women, and carrying a body mass index between 22.0 and just under 28.0, which places them in the normal to modestly overweight range rather than the obese range where calorie reduction is a treatment for something. Randomization ran about two to one in favour of restriction, giving 143 in the restricted arm and 75 controls at baseline. The prescription was a 25 percent cut in energy intake sustained for two years, supported by structured behavioural counselling rather than by supplied meals. That design choice matters. CALERIE tested whether free-living adults could restrict intake in the real world and what happened to them if they did, which is a different and more useful question than what happens to a caged animal fed a measured ration.
The Trial Asked for a Quarter and Got Roughly a Tenth
Percent reduction in energy intake in the CALERIE Phase 2 restricted arm, prescribed against delivered. The protocol asked participants to cut intake by 25 percent for two years. Measured adherence came in at 15.2 percent at month 12 and 11.9 percent averaged across the full 24 months, with the month 24 figure closer to 10 percent depending on the estimation method used. Every downstream result in the trial belongs to that smaller number, not the headline one. This matters for interpretation, because it means CALERIE tested moderate sustained restriction in free-living adults rather than the severe restriction that produces the largest effects in rodent studies.
How much restriction did participants actually achieve?
Participants achieved about half of what the protocol prescribed, averaging 11.9 percent restriction across the two years rather than 25 percent. Adherence was best early and drifted afterwards, with measured intake reduction sitting near 15.2 percent at month 12 and closer to 10 percent by month 24 depending on the estimation method. This is the single most important detail for interpreting everything downstream, and it is the detail most often dropped. When someone cites CALERIE as showing what 25 percent caloric restriction does to a human, they are quoting a prescription rather than an exposure. The trial actually reports what roughly 12 percent restriction does over 24 months. That is a meaningful intervention and it produced meaningful results, but it sits well below the 30 to 40 percent restriction that generates the large lifespan effects in rodent studies. It also tells you something about feasibility that no amount of mechanism can. These were volunteers who signed up for a two-year restriction trial, were screened for psychological suitability, and received ongoing professional support at an academic research centre. Under those conditions, sustained restriction landed near a tenth of intake. Whatever caloric restriction can do in principle, this is roughly the dose a motivated person delivers in practice.
Where the Seven and a Half Kilograms Came From
Mass lost in the CALERIE restricted arm at month 24, broken down by compartment, in kilograms. Total weight loss was 7.6 kilograms, about 10.4 percent of starting body weight, after a peak loss of 8.3 kilograms at month 12. Of the mass still gone at two years, roughly 5.4 kilograms was fat and 2.0 kilograms was fat-free tissue, which includes muscle, organ mass and the water they carry. Trunk fat accounted for 2.8 kilograms and waist circumference fell 6.1 centimetres. The fat-free bar is the one worth sitting with, because it represents roughly a quarter of the total and it came out of people who were not overweight to begin with.
Did caloric restriction actually slow biological aging?
One of six aging measures moved, and it moved by about 3 percent. The analysis that generated the headlines was published in Nature Aging in 2023 by Waziry and colleagues, who applied a panel of DNA methylation algorithms to blood samples from CALERIE participants at baseline, month 12 and month 24. DunedinPACE was the one that responded. It is worth understanding what makes DunedinPACE different from the others. Clocks like Horvath, Hannum, PhenoAge and GrimAge estimate biological age as an accumulated level, a stock of damage. DunedinPACE was trained on the rate of change in 19 biomarkers measured across 20 years in the Dunedin birth cohort, so it estimates how fast a person is currently aging rather than how much aging they have already done. In CALERIE the restricted group showed a slowing of roughly 2 to 3 percent on that measure, statistically significant in the intent-to-treat analysis. PhenoAge, GrimAge, Horvath and Hannum showed no significant change. A separate analysis found that markers of cellular senescence fell in the restricted group. Three percent sounds trivial, and the honest counterargument is that in an independent cohort of older adults a 3 percent slower DunedinPACE reading was associated with roughly 15 percent lower mortality risk. That association is not the same thing as a demonstrated benefit, because nobody has followed CALERIE participants long enough to count deaths, but it is the reason the finding was taken seriously rather than dismissed.
One Clock Moved. The Others Did Not.
A schematic map of every aging readout CALERIE has reported. Sky marks measures that moved in the direction restriction was supposed to move them, dark grey marks measures that did not move at all, and slate marks a measure that moved the wrong way. DunedinPACE, which estimates the current rate of aging rather than accumulated damage, slowed by roughly 2 to 3 percent in the restricted group. PhenoAge, GrimAge, Horvath and Hannum, which estimate biological age as a level rather than a rate, showed no significant change. Telomere attrition ran faster in the restricted group during the first year while weight was actively falling. Reading a single positive result out of six as proof that restriction slows aging is the mistake this chart exists to prevent.
What happened to cardiometabolic risk factors?
Cardiometabolic risk improved across essentially every marker the trial measured, and this is the strongest result CALERIE produced. Kraus and colleagues published the cardiometabolic outcomes in The Lancet Diabetes and Endocrinology in 2019. LDL cholesterol fell from 97 to 90 milligrams per decilitre and triglycerides from 102 to 88. Systolic blood pressure dropped 2.2 millimetres of mercury and diastolic 3.4. Fasting insulin and HOMA-IR, the standard index of insulin resistance, fell by 20 to 30 percent. C-reactive protein, the most widely used marker of systemic inflammation, dropped roughly 40 to 50 percent relative to the control group. Waist circumference fell 6.1 centimetres. What makes these numbers notable is not their size, which is comparable to what any successful weight loss intervention produces, but the starting point. These participants were already healthy and already had risk factors below clinical treatment thresholds. Moving LDL from 97 to 90 in a person whose LDL is not a problem is a different observation from moving it in someone with established cardiovascular disease, and the investigators framed it as evidence that risk can be pushed below the range where medicine normally intervenes. Whether doing so translates into fewer events decades later is untested. It is a reasonable hypothesis with a substantial epidemiological basis behind it, and it is not something CALERIE measured.
What did two years of restriction do to bone?
Bone mineral density fell at every site measured, by roughly 2 percent at the lumbar spine and femoral neck, while the control group held steady or gained. Villareal and colleagues reported the bone analysis in the Journal of Bone and Mineral Research in 2016, covering 218 participants at a mean age of 37.9 years. Over 24 months the restricted group changed by minus 0.013 grams per square centimetre at the lumbar spine against plus 0.007 in controls at p below 0.001, minus 0.017 against plus 0.001 at the total hip at p below 0.001, and minus 0.015 against minus 0.005 at the femoral neck at p equals 0.03. Bone resorption markers including C-terminal telopeptide rose over the same period, which indicates the density loss reflected genuine bone turnover rather than a measurement artefact of shrinking body mass. One participant was withdrawn from the trial specifically for excessive bone mineral density loss, alongside two withdrawn for falling hematocrit. Context matters here in both directions. These were adults in their thirties with normal bone who lost density they could afford to lose over two years, and skeletal loading falls when body weight falls, so some decline is expected and partly reversible. The uncomfortable extrapolation is to the population most interested in longevity interventions, which is men in their fifties and sixties who are already losing bone for age-related reasons and who were not enrolled in this trial. Nobody has run CALERIE in that group, and the femoral neck is where hip fractures happen.
The Skeleton Kept a Record of the Two Years
Change in bone mineral density in grams per square centimetre over 24 months, restricted group against the ad libitum control, from the CALERIE bone analysis published in the Journal of Bone and Mineral Research in 2016 with 218 participants at a mean age of 37.9 years. The restricted group lost density at all three sites while the control group held or gained: lumbar spine minus 0.013 against plus 0.007 at p below 0.001, total hip minus 0.017 against plus 0.001 at p below 0.001, and femoral neck minus 0.015 against minus 0.005 at p equals 0.03. In relative terms that is roughly 2 percent lower density at the lumbar spine and femoral neck. Bone resorption markers rose in parallel, which indicates the loss came from active bone breakdown rather than from measurement drift.
- Calorie restriction
- Ad libitum control
What happened to testosterone and sexual function in the men?
Sex hormone binding globulin rose significantly in the restricted men, free testosterone fell at month 12, and both had largely settled by month 24 without any deterioration in sexual function. Martin and colleagues reported these outcomes in JAMA Internal Medicine in 2016 as part of the mood, quality of life, sleep and sexual function analysis. In the male-only analysis, SHBG increased at both month 12 and month 24 at p below 0.001 in each case. Since SHBG binds testosterone and removes it from circulation in a usable form, a rise in SHBG pushes free testosterone down even when total testosterone holds. Free testosterone did fall at month 12, and the reduction was described as temporary, having resolved by month 24. The part that surprises people is what did not happen. Across the measured domains of sexual cognition and fantasy, arousal, behaviour and experience, orgasm, and drive, the restricted men showed no deterioration, and the sexual drive and relationship subscale actually improved at month 24 at p equals 0.03. Mood improved modestly, with a 0.76 point gain on the Beck Depression Inventory, and general health perception improved by 6.45 points. Sleep quality showed no significant between-group difference. The reasonable reading is that a rise in SHBG during active weight loss is a predictable physiological response to a negative energy balance rather than a sign of gonadal suppression, and that in healthy men under 50 it did not translate into symptoms. Whether the same holds for a 58 year old man with a total testosterone already near the lower reference limit is a question the trial did not ask.
Did participants lose muscle, and what happened to metabolic rate?
About a quarter of the mass lost was fat-free tissue, absolute strength declined, and resting metabolic rate fell roughly 5 percent without evidence of a lasting metabolic adaptation. Of the 7.6 kilograms still gone at month 24, roughly 5.4 kilograms was fat mass and 2.0 kilograms was fat-free mass. Knee extensor and flexor strength declined 3 to 7 percent in absolute terms, though strength relative to body weight improved 4 to 6 percent because the body being moved had got lighter. Maximal oxygen uptake told the same story from the other direction, rising about 5 percent per kilogram of body mass in the restricted group against a 3 percent decline in controls, which reflects a smaller body more than a better engine. Resting metabolic rate fell 5.9 percent at month 12 and 5.0 percent at month 24, and total energy expenditure remained below baseline throughout. The important nuance is that the metabolic rate residual, which is the part of the decline that cannot be explained by the loss of metabolically active tissue, was similar between groups at month 24. In plain terms, the body burned less because there was less of it, not because restriction had installed a permanently thriftier metabolism. Losing 2.0 kilograms of fat-free mass is the finding that should give a lifter pause. In a healthy 38 year old that loss is recoverable with training and protein. In a man past 55 who is already losing lean mass at roughly 1 percent a year, deliberately shedding another 2 kilograms of it is a trade with a different arithmetic behind it.
Why did telomeres shorten faster in the restricted group?
Telomere attrition ran faster in the restricted group during the first year, the year in which weight was actively falling, and the trajectory changed once weight stabilized. Hastings and colleagues published the telomere analysis in Aging Cell in 2024, measuring both assayed telomere length and a DNA methylation based estimate. Over the first year, the participants cutting calories lost telomere length more rapidly than controls. The intent-to-treat analysis did not find those first-year differences statistically significant, though the trend ran toward greater attrition in the restricted group on both measures, and the pattern shifted in year two after weight had plateaued. There is no settled explanation. One reading is that active weight loss is itself a physiologically demanding state involving elevated cell turnover, and that the cost shows up in leukocyte telomeres before the benefit does. Another is that leukocyte telomere length is a noisy and much-criticised biomarker that responds to shifts in immune cell composition as readily as to anything happening to the cells themselves. The result is worth knowing about for two reasons. It is a genuine finding from the same trial that produced the DunedinPACE headline, and it points in the opposite direction, which is a useful corrective for anyone treating aging biomarkers as if they all measure the same underlying thing. On a site that writes frequently about telomere biology, it also underlines that a telomere reading is one instrument among several, and instruments disagree.
What should a man over 40 actually take from CALERIE?
CALERIE supports moderate sustained restriction as a way to improve cardiometabolic risk in healthy adults under 50, and it does not support caloric restriction as a proven longevity intervention in humans. The honest summary of two years of data is that eating about 12 percent less than you otherwise would produced roughly 10 percent weight loss, a broad improvement in lipids, blood pressure, insulin sensitivity and inflammation, a small improvement in mood and general health perception, no loss of sexual function in the men, a 3 percent slowing on one aging clock out of six, roughly 2 percent lower bone density at the spine and femoral neck, and 2 kilograms of lost fat-free mass. Nothing in that list is a lifespan result, because no human caloric restriction trial has ever measured lifespan, mortality or incident disease. The generalisation problem is the harder one. CALERIE enrolled healthy men aged 21 to 50 with a body mass index under 28, which excludes most of the men reading about longevity interventions. The two findings that scale worst into an older population are the bone loss and the lean mass loss, both of which land on a skeleton and a muscle mass that are already declining for reasons unrelated to diet. Anyone considering sustained restriction past middle age has an obvious set of countermeasures worth discussing with a physician, including resistance training, adequate protein intake, vitamin D and calcium status, and baseline bone density measurement rather than assuming the skeleton will tolerate it. This article is educational and is not medical advice, and no regulator has approved caloric restriction as a treatment for aging or any disease.
The CALERIE Record on One Axis
Every strand of the CALERIE evidence arranged as a single schematic map. Sky marks what the trial supports, amber marks findings that are real but narrower or more double-edged than the headline suggests, slate marks results that count against the practice, and dark grey marks claims the trial cannot carry. CALERIE is the best human caloric restriction evidence that exists and it is genuinely impressive on cardiometabolic risk. It is also a two-year trial in healthy adults under 50 that delivered about half the restriction it prescribed, moved one aging clock out of six, and took measurable density off the hip and spine. Nobody has run it in older men, and nobody has followed anyone long enough to count deaths.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.